Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$881,665 Mln
Revenue (TTM)
$65,179 Mln
Net Profit (TTM)
$20,638 Mln
ROE
1 %
ROCE
35.3 %
P/E Ratio
42.9
P/B Ratio
32.9
Industry P/E
--
EV/EBITDA
28.6
Div. Yield
0.6 %
Debt to Equity
1.6
Book Value
$29.5
EPS
$23
Face value
--
Shares outstanding
892,992,420
CFO
$53,052.40 Mln
EBITDA
$75,012.70 Mln
Net Profit
$38,462.90 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
| -14.6 | -11.4 | -11.9 | 11.3 | 40.8 | 37.5 | 29.5 |
|
BSE Sensex*
| -11.4 | -10.4 | -11.2 | -0.4 | 9.0 | 8.8 | 11.6 |
|
S&P 100
| -6.3 | -3.3 | -3.8 | 18.0 | 21.9 | 12.4 | 13.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
| 39.2 | 32.1 | 59.3 | 32.4 | 63.6 | 28.5 | 13.6 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Eli Lilly and Company (LLY)
|
918.1 | 881,665.1 | 65,179.0 | 20,638.3 | 40.5 | 101.3 | 42.9 | 32.9 |
| 208.3 | 388,431.4 | 61,160.0 | 4,226.0 | 15.4 | 15367.3 | 92.7 | 50.5 | |
| 351.5 | 197,412.0 | 36,741.0 | 7,711.0 | 36.8 | 106.1 | 25.7 | 22.9 | |
| 59.4 | 120,314.9 | 48,194.0 | 7,053.0 | 22.2 | 40.5 | 17.1 | 6.5 | |
| 141.3 | 179,993.6 | 29,443.0 | 8,510.0 | 28.8 | 40.6 | 21.4 | 7.9 | |
| 237.3 | 582,038.9 | 94,193.0 | 26,804.0 | 34.6 | 35 | 21.9 | 7.2 | |
| 920.4 | 116,133.4 | 397,958.0 | 4,340.0 | 1.5 | -- | 27.2 | 5.0 | |
| 114.5 | 285,833.2 | 65,011.0 | 18,254.0 | 33.9 | 36.9 | 15.9 | 5.4 | |
| 149.8 | 296,610.3 | 54,811.3 | 14,055.6 | 31.2 | 31.2 | 21.5 | 6.3 | |
| 27.3 | 151,141.0 | 62,579.0 | 7,770.0 | 16.3 | 8.9 | 19.5 | 1.7 |
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog,... Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Read more
Chairman, CEO & President
Mr. David A. Ricks
Executive VP, General Counsel & Secretary
Ms. Anat Hakim J.D.
Headquarters
Indianapolis, IN
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Eli Lilly and Company (LLY) is $918.05 (NYSE) as of 18-Mar-2026 16:25 EDT. Eli Lilly and Company (LLY) has given a return of 40.76% in the last 3 years.
The P/E ratio of Eli Lilly and Company (LLY) is 42.92 times as on 13-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
46.76
|
36.37
|
|
2024
|
65.84
|
49.13
|
|
2023
|
100.55
|
48.92
|
|
2022
|
55.66
|
32.64
|
|
2021
|
47.19
|
29.34
|
The 52-week high and low of Eli Lilly and Company (LLY) are Rs 1,133.95 and Rs 623.78 as of 19-Mar-2026.
Eli Lilly and Company (LLY) has a market capitalisation of $ 881,665 Mln as on 13-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Eli Lilly and Company (LLY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-12.30
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.